News

The company’s development product candidate NeuVax is the immunodominant nonapeptide derived from the extracellular domain of the HER2 protein, a well-established target for therapeutic intervention in breast carcinoma.

The building, which will be built with an investment of about JPY2.22bn ($21.9m), is expected to be completed in March 2015. The construction project is part of the

IPF causes scarring of the lungs, irreversibly destroying normal lung architecture and hindering a person’s ability to breathe. The disease typically occurs in patients over the age of

MEI Pharma is a US-based oncology firm focused on the clinical development of novel therapies for cancer. Pracinostat is an orally available histone deacetylase (HDAC) inhibitor that has

Based on this amendment, the territories subject to the License Agreement have been changed to reflect that Astellas will be responsible for all regulatory filings and will exclusively

The CHMP positive opinion will be reviewed by the European Commission, which if approved, grants a centralized marketing authorization with unified labeling that is valid in the 28

The two distinct properties could result in a unique therapeutic profile for SYN120 combining pro-cognitive and antipsychotic activities. SYN120 has completed single and multiple ascending dose Phase I

The company also announced a $15m investment by Perrigo to acquire approximately 7% of Transition’s common shares. ELND005 is an oral drug candidate that is being evaluated in

Otsuka, in accordance with the MOU, has engaged in a wide range of capital expenditures for the manufacture of pharmaceutical products, including investment in research and development of